Dr. Nur Syamimi Ariffin completed her Ph.D. in Pharmacology from the University of Manchester in 2017. During her Ph.D., she worked on the role of the transcription factor RUNX1-CBFβ complex as a molecular target to prevent breast cancer metastasis. She used pharmacological and molecular genetic approaches to achieve her goals, one of which was to establish a knockout cell line using a double nickase CRISPR-Cas9 strategy. She obtained her Master’s degree from the University of Otago in 2012 and received her first degree in Biomedicine from Universiti Putra Malaysia in 2008. She is currently working as a Senior Lecturer at the Faculty of Pharmacy, Universiti Teknologi MARA. She teaches Pharmacology and Toxicology and is developing her research in deciphering the transcriptional networks involving RUNX1 in breast cancer.
Molecular cancer (Advance techniques in molecular cancer studies)
Genetics (Role of transcription factors in gene regulations)